NEWS

After several years of steady growth, Europe’s drug regulators are once again increasing the pace of recommended medicines for approval.   Last year, European authorities recommended 38 new active substances, delivering a second straight year of elevated output. Even so, Europe continues to lag well behind the U.S., which approved 53 novel medicines, roughly 30% more, according to Endpoints News .   As U.S. policymakers weigh whether to adopt foreign-style pricing frameworks

We Work For Health Executive Director Dan Leonard issued the following statement in response to the Center for Medicare & Medicaid Services’ (CMS) announcement of the next selection of drugs in Medicare to be negotiated under the Inflation Reduction Act (IRA):   “As the Administration continues to add drugs to this list, it reinforces a troubling path driven by misguided and flawed efforts to advance government price controls under the Inflation Reduction Act. This trend is f

America's biopharmaceutical sector is delivering unprecedented economic impact across the nation. Since January 2025, companies have committed more than $582 billion  to bolster U.S. research and development, expand manufacturing and create jobs in communities nationwide. From cutting-edge manufacturing facilities in the South to next-generation research hubs in the Mid-Atlantic, the life sciences industry is driving local economic growth, creating high-skill jobs and ensurin

We Work For Health Executive Director Dan Leonard recently sat down with Dr. Rachel Brem, Director of the Breast Imaging and Interventional Center at George Washington University and Co-Founder and Chief Medical Officer of the Brem Foundation. Dr. Brem has pioneered multiple breakthrough technologies for early breast cancer detection and brings a unique perspective – both professional and deeply personal – on what it takes to translate medical innovation into life-saving care

According to a recent report from the American Cancer Society, the five-year survival rate for cancer in the United States has significantly improved. In the mid-1970s, only half  of cancer patients would survive five years or more, now seven in 10 survive. Thanks to technological innovation leading to life-saving cures, cancer survival is increasingly achievable. For cancer patients, these medical innovations add years to their lives. The recent study shows remarkable progr

We appreciate the administration's continued focus on making healthcare more affordable for American families. The rising cost is a genuine concern, and policymakers are right to demand accountability from those responsible. That's why we commend the administration's and Congress’ efforts to hold healthcare middlemen, including corporate insurers and their subsidiaries, accountable for their anti-competitive practices and opacity that drive up costs throughout the entire syst

Evidence continues to show that government price control policies like the Inflation Reduction Act (IRA) slow drug innovation, particularly for small molecule medications, which are typically found in pill and tablet form.   Late last year, the University of Chicago’s Kenneth C. Griffin Department of Economics published research revealing unintended consequences of the IRA on oncology drug development. The University of Chicago’s researchers examined 184 cancer drugs approve

This week, two major research reports were released that offer fresh industry insight into China’s rapid biopharma growth and the potential impact on U.S. global competitiveness.   McKinsey & Company  highlighted China’s undisputed foothold as Asia’s innovation leader. As countries like South Korea and India have stood out, combining ambition with strategic investment to build their capabilities, China is responsible for nearly a third of the global pipeline. TD Cowen collec